FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

vvasiiiigtori	D.C. 20549	

OIVIB API	PROVAL
OMB Number:	3235-0287
Estimated average	e burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Farnum Rhonda				2. Issuer Name and Ticker or Trading Symbol Theravance Biopharma, Inc. [TBPH]							(Che	eck all app	ng Person(s) to Issuer 10% Owner Other (specify		ner			
	(Last) (First) (Middle) C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BLVD				3. Date of Earliest Transaction (Month/Day/Year) 11/11/2024							7 -	below) SVP, COMM & MEDICAL AFFAIRS					
(Street) SOUTH SAN FRANCISCO CA 94080				4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(St	ate) (Ž	Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,		Transaction Di			. Securities Acquired (A Disposed Of (D) (Instr. 3, D)			Benefic Owned	ies ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) o	r	Price	Reporte Transa (Instr. 3	ction(s)		(In	(Instr. 4)
Ordinary Shares 11/11/.				2024		S		4,000	D		\$ 9	32	322,743					
·		Tal					ies Acqui varrants,							y Owned	t			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	Transaction o		of	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amount of Securities S		3. Price of Derivative Gecurity Securities Beneficially		Owners Form:	hip	11. Nature of Indirect Beneficial Ownership		

Explanation of Responses:

Security

Remarks:

This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 03/14/2024.

/s/ Brett A. Grimaud, 11/13/2024 Attorney-in-Fact

Following Reported Transaction(s) (Instr. 4)

or Indirect (I) (Instr. 4)

** Signature of Reporting Person Date

Title

Security (Instr. 3 and 4)

Amount or Number

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

٧

Acquired (A) or Disposed of (D) (Instr. 3, 4

and 5)

(A) (D) Date

Expiration

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.